Read More

Genetic Technologies Announced Earlier Upcoming Launch Of World’s First Comprehensive Risk Test For Breast & Ovarian Cancer

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the Company will launch a ‘World First' Comprehensive Risk Assessment Test which evaluates a women's risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.

GENE

Read More

Genetic Technologies Announced GeneType Published in PLOS ONE – Development of Polygenic Risk Scores for Cardiovascular Diseases and Type 2 Diabetes

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the g

GENE

Read More

Genetic Technologies Named Tony Di Pietro as CFO

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the appointment of experienced Chief Financial Officer, Mr Tony Di Pietro. Tony will also be appointed as Company Secretary upon his arrival. Mr Di Pietro is a Chartered Accountant and an Associate of the Governance Institute Australia with 18 years Biotechnology industry experience.

GENE